ONRELTEA Gel (Brimonidine 0.33%)
ONRELTEA is the Canadian name for the US FDA approved treatment from Galderma that is called Mirvaso. ONRELTEA is the only topical treatment officially approved for the relief of the red face of rosacea. ONRELTEA is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours. See below for ONRELTEA reviews, news and updates or see the Mirvaso Articles for information on the equivalent prescription.
Recent Rosacea Blog Posts
Users of ONRELTEA in Canada who have bad reactions or `adverse events’ related to using this newly approved product are reminded in the ONRELTEA Product Monograph to report these events. The body responsible for supervising prescription drugs is the Canada Vigilance Program. The Brimonidine based topical which is available in the US as Mirvaso has […]
Galderma, for reasons unknown, decided to rebrand the newly FDA approved Mirvaso as ONRELTEA in Canada (yes they use all capitals in the brand name). This continues the tradition for Galderma of split North American branding; Oracea in the US is known as Efracea in Canada. There is already some history of user experiences of […]
Galderma has reached into its bag of trademarks and announced that Mirvaso will be known as ONRELTEA in Canada. Red Faced? Rosacea Sufferers Now Have a New Option Proven to Reduce Facial Redness Health Canada Approves The First and Only Topical Treatment Indicated for the Persistent Facial Erythema of Rosacea THORNHILL, ON, May 21, 2014 […]
